Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentActive18 and overNCI, OtherRTOG-1205
NCI-2012-01732, U10CA021661, NCT01730950

Trial Description

Summary

This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma

Further Study Information

PRIMARY OBJECTIVES:

I. To establish an improvement in overall survival in recurrent glioblastoma (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.

SECONDARY OBJECTIVES:

I. To estimate and compare the rate of objective response in patients with measurable disease.

II. To estimate and compare the 6-month progression-free survival rate. III. To estimate and compare progression-free survival. IV. To estimate and compare the rate of treatment adverse events. V. To estimate and compare the rate of grade 3+ acute or delayed central nervous system (CNS) toxicity.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks.

ARM II: Patients receive bevacizumab as patients in arm I and undergo radiation therapy using intensity-modulated radiation therapy (IMRT), 3-dimensional conformal radiation therapy (3D-CRT), or proton beam radiation therapy (RT) 5 days a week for 2 weeks.

In both arms, courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 1 year, every 6 months for 1 year and then annually thereafter.

Eligibility Criteria

Inclusion Criteria:

  • Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made
  • Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) CT scan within 21 days prior to registration
  • Patients also must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:
  • New areas of tumor outside the original radiotherapy fields as determined by the investigator, or
  • Histologic confirmation of tumor through biopsy or resection, or
  • Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration
  • Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement
  • Prior history of standard dose CNS radiation of 60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower doses
  • Patients who have received prior treatment with non-standard radiation therapy (RT) dose and fractionation, interstitial brachytherapy, stereotactic radiosurgery, etc. are eligible
  • Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of 28 days prior to registration from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:
  • 14 days from administration of vincristine
  • 42 days from administration of nitrosoureas
  • 21 days from administration of procarbazine
  • Patients having undergone recent resection of their glioblastoma (within 5 weeks prior to registration) must have recovered from the effects of surgery; for CNS related core or needle biopsies, a minimum of 7 days must have elapsed prior to registration
  • Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative or intra-operative MRI scan (or CT scan for patients with non-compatible devices) must be performed prior to registration and should be within 96 hours post surgery (although 24 hours would be optimum)
  • History/physical examination, including neurologic examination, within 14 days prior to registration
  • Karnofsky performance status >= 60 within 14 days prior to registration
  • Complete blood count (CBC)/differential obtained within 14 days prior to registration, with adequate bone marrow function
  • Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
  • Platelets >= 75,000 cells/mm^3
  • Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin (Hgb) >= 9.0 g/dl is acceptable)
  • Total bilirubin =< 2.0 mg/dL
  • Serum glutamic oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal
  • Serum creatinine =< 1.8 mg/dL
  • Urine protein creatinine (UPC) ratio >= 1.0 within 14 days prior to registration OR urine dipstick for proteinuria >= 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =< 1g of protein in 24 hours to be eligible)
  • Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm; UPC ratio is calculated using one of the following formulas:
  • [urine protein]/[urine creatinine]: if both protein and creatinine are reported in mg/dL
  • [(urine protein) x 0.088]/[urine creatinine]: if urine creatinine is reported in mmol/L
  • Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within 14 days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on trial and for 6 months after
  • Patients on full-dose anticoagulants (e.g., warfarin or low molecular weigh [LMW] heparin) must meet both of the following criteria:
  • No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
  • In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
  • Patient must be able to provide study-specific informed consent prior to study entry

Exclusion Criteria:

  • More than three relapses
  • Infratentorial or leptomeningeal evidence of recurrent disease
  • Recurrent or persistent tumor greater than 6 cm in maximum diameter
  • Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGFR (including bevacizumab)
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Severe, active co-morbidity, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
  • Transmural myocardial infarction within the last 6 months prior to registration
  • History of stroke or transient ischemic attack within 6 months prior to registration
  • Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function other than screening panel and coagulation parameters are not required for entry into this protocol
  • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol specific requirements may also exclude immuno-compromised patients
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
  • Prior allergic reaction to the study drug (bevacizumab)
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration
  • Gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

  • National Cancer Institute
Christina Tsien, Principal Investigator
Jeffrey J. Raizer, Study Chair
Adam P. Dicker, MD, PhD, Study Chair
Martha M. Matuszak, PhD, Study Chair

Trial Sites

U.S.A.

Alabama
Birmingham

UAB Comprehensive Cancer Center

John Fiveash
Ph: 205-934-0309

Mobile

University of South Alabama Mitchell Cancer Institute

John Ronald Russell
Ph: 877-904-4367
Email: pfrancisco@usouthal.edu

Arizona
Phoenix

St. Joseph's Hospital and Medical Center

David G. Brachman
Ph: 877-602-4111

Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 877-602-4111

California
Burbank

Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Dublin

Epic Care-Dublin

James H. Feusner
Ph: 510-450-7600

Fresno

Fresno Cancer Center

Samantha A Seaward
Ph: 626-564-3455

Los Angeles

Kaiser Permanente Medical Center - Los Angeles

Michael R Girvigian
Ph: 626-564-3455

Oakland

Kaiser Permanente-Oakland

Samantha A Seaward
Ph: 626-564-3455

Rancho Cardova

Kaiser Permanente Medical Center - Rancho Cordova

Samantha A Seaward
Ph: 626-564-3455

Rohnert Park

Rohnert Park Cancer Center

Samantha A Seaward
Ph: 626-564-3455

Roseville

The Permanente Medical Group-Roseville Radiation Oncology

Samantha A Seaward
Ph: 626-564-3455

Sacramento

South Sacramento Cancer Center

Samantha A Seaward
Ph: 626-564-3455

Santa Clara

Kaiser Permanente Medical Center - Santa Clara Homestead Campus

Samantha A Seaward
Ph: 626-564-3455

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha A Seaward
Ph: 626-564-3455

Walnut Creek

John Muir/Mt. Diablo Comprehensive Cancer Center

Daniel M. Chinn
Ph: 925-674-2580

Colorado
Boulder

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Colorado Springs

Memorial Hospital Cancer Center - Colorado Springs

Brian D Kavanagh
Ph: 720-848-0650

Penrose Cancer Center at Penrose Hospital

Keren Sturtz
Ph: 888-785-6789

Fort Collins

Poudre Valley Hospital

Brian D Kavanagh
Ph: 720-848-0650

Longmont

Hope Cancer Care Center at Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Connecticut
Bridgeport

St. Vincent's Medical Center

Nicholas A Blondin
Ph: 203-576-6329
Email: twhite@stvincents.org

New Britain

George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus

Neal B Goldberg
Ph: 860-224-5660

Florida
Deerfield Beach

University of Miami/Deerfield Beach

Fazilat Ishkanian
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Jacksonville

Baptist Cancer Institute - Jacksonville

Mark E Augspurger
Ph: 904-202-7051

Miami

University of Miami Sylvester Comprehensive Cancer Center - Miami

Fazilat Ishkanian
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Georgia
Atlanta

Emory University Hospital Midtown

Ian R Crocker
Ph: 404-778-1868

Northside Hospital Cancer Center

Sahar E Rosenbaum
Ph: 404-303-3355

Piedmont Hospital

Adam W Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Winship Cancer Institute of Emory University

Ian R Crocker
Ph: 404-778-1868

Cumming

Northside Hospital-Forsyth

Sahar E Rosenbaum
Ph: 404-303-3355

Hawaii
Honolulu

Queen's Cancer Institute at Queen's Medical Center

Paul A. DeMare
Ph: 808-545-8548

Idaho
Boise

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

Samir Narayan
Ph: 734-712-4673

Illinois
Chicago

John H. Stroger, Jr. Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Jeffrey J. Raizer
Ph: 312-695-1301
Email: cancer@northwestern.edu

University of Chicago Cancer Research Center

Steven J Chmura
Ph: 773-834-7424

Joliet

Joliet Oncology-Hematology Associates, Limited - West

Kulumani M Sivarajan
Ph: 815-730-3098
Email: maureenc@jolietoncology.com

New Lennox

Silver Cross Hospital

Steven J Chmura
Ph: 773-834-7424

Warrenville

Central Dupage Cancer Center

Vinai Gondi
Ph: 630-352-5300

Indiana
Indianapolis

Methodist Cancer Center at Methodist Hospital

Mark P Langer
Ph: 317-274-2552

South Bend

Memorial Hospital of South Bend

David A. Hornback
Ph: 800-284-7370

Kentucky
Lexington

Central Baptist Hospital

Marta S Hayne
Ph: 859-260-6425

University of Kentucky Chandler Medical Center

John L Villano
Ph: 859-257-3379

Louisville

Louisville Oncology at Norton Cancer Institute - Louisville

Aaron C Spalding
Ph: 502-629-2500

University of Louisville School of Medicine

Shiao Y Woo
Ph: 866-530-5516

Maine
Scarborough

Maine Medical Center- Scarborough Campus

Ian J Bristol
Ph: 207-396-8090
Email: wrighd@mmc.org

Maryland
Baltimore

Greenebaum Cancer Center at University of Maryland Medical Center

Young Kwok
Ph: 800-888-8823

Bel Air

Upper Chesapeake Medical Center

Young Kwok
Ph: 800-888-8823

Massachusetts
Boston

Dana-Farber/Brigham and Women's Cancer Center

Kevin S Oh
Ph: 877-726-5130

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

Kevin S Oh
Ph: 877-726-5130

Massachusetts General Hospital

Kevin S Oh
Ph: 877-726-5130

Burlington

Lahey Clinic Medical Center - Burlington

Brian J Scott
Ph: 781-744-8027

Lowell

Lowell General Hospital

Matthew S Katz
Ph: 978-788-7084
Email: ghincks@lowellgeneral.org

Springfield

Baystate Medical Center

Seth A Kaufman
Ph: 413-794-9338

Michigan
Ann Arbor

Saint Joseph Mercy Cancer Center

Samir Narayan
Ph: 734-712-4673

University of Michigan Comprehensive Cancer Center

Christina I. Tsien
Ph: 734-936-4307
Email: ctsien@umich.edu

Detroit

Van Elslander Cancer Center at St. John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Pontiac

St. Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Warren

St. John Macomb Hospital

Samir Narayan
Ph: 734-712-4673

Minnesota
Bemidji

MeritCare Bemidji

Preston D. Steen
Ph: 701-234-6161

Mississippi
Jackson

University of Mississippi Cancer Clinic

Mark D Anderson
Ph: 601-815-6700

Missouri
Rolla

Phelps County Regional Medical Center

Jay W Carlson
Ph: 800-821-7532

Saint Louis

Barnes-Jewish West County Hospital

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

Jiayi Huang
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Springfield

St. John's Regional Health Center

Jay W Carlson
Ph: 800-821-7532

Montana
Billings

Billings Clinic Cancer Center - 801 N 29th Street

Benjamin Thomas Marchello
Ph: 800-648-6274

Nebraska
Omaha

Methodist Estabrook Cancer Center

Tien-Shew W Huang
Ph: 402-354-5144

Nevada
Henderson

Comprehensive Cancer Centers of Nevada - Henderson

John Allan Ellerton
Ph: 702-384-0013

Las Vegas

Cancer Institute of Nevada at Summerlin Hospital Medical Center

John Allan Ellerton
Ph: 702-384-0013

Comprehensive Cancer Centers of Nevada - Central Valley

John Allan Ellerton
Ph: 702-384-0013

Comprehensive Cancer Centers of Nevada - Northwest

John Allan Ellerton
Ph: 702-384-0013

Comprehensive Cancer Centers of Nevada - Southwest

John Allan Ellerton
Ph: 702-384-0013

Reno

Saint Mary's Regional Medical Center

Jonathan S Tay
Ph: 775-770-7414

New Jersey
Mount Holly

Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

New Brunswick

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Sharad Goyal
Ph: 732-235-8675

Voorhees

Fox Chase Virtua Health Cancer Program at Virtua West Jersey

Lemuel S. Ariaratnam
Ph: 888-847-8823

New York
Bay Shore

Southside Hospital

Jonathan P. S. Knisely
Ph: 516-562-3467

Bronx

Montefiore Medical Center

Mary R Welch
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

New Hyde Park

Monter Cancer Center of the North Shore-LIJ Health System

Jonathan P. S. Knisely
Ph: 516-562-3467

New York

St. Luke's - Roosevelt Hospital Center - St.Luke's Division

Rahul R Parikh
Ph: 212-824-7320
Email: jenny.figueroa@mssm.edu

Rochester

James P. Wilmot Cancer Center at University of Rochester Medical Center

Yuhchyau Chen
Ph: 585-275-5830

North Carolina
Gastonia

CaroMont Cancer Center at Gaston Memorial Hospital

Charles J. Meakin
Ph: 704-834-2932

North Dakota
Bismarck

Medcenter One Hospital Cancer Care Center

Preston D. Steen
Ph: 701-234-6161

Fargo

Roger Maris Cancer Center at MeritCare Hospital

Preston D. Steen
Ph: 701-234-6161

Ohio
Akron

McDowell Cancer Center at Akron General Medical Center

Mitchell Lee Fromm
Ph: 330-344-6348

Summa Center for Cancer Care at Akron City Hospital

Charles A Kunos
Ph: 330-375-6101

Barberton

Barberton Citizens Hospital

Charles A Kunos
Ph: 330-375-6101

Cleveland

Case Comprehensive Cancer Center

Simon Shek-Man Lo
Ph: 800-641-2422

Columbus

Riverside Methodist Hospital Cancer Care

J. Philip Kuebler
Ph: 614-566-3275

Kettering

Charles F. Kettering Memorial Hospital

Howard M. Gross
Ph: 937-775-1350

Oklahoma
Oklahoma City

Central Oklahoma Cancer Center at INTEGRIS Southwest Medical Center

Gary L Larson
Ph: 405-949-3870

Stephenson Cancer Center at the University of Oklahoma

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Portland

Legacy Good Samaritan Hospital & Comprehensive Cancer Center

Andrew Y Kee
Ph: 507-538-7623

Providence Cancer Center at Providence Portland Medical Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Providence St. Vincent Medical Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Pennsylvania
Beaver

UPMC Cancer Center at Beaver Medical Center

John C Flickinger
Ph: 412-647-2811

Bethlehem

St. Luke's Cancer Network at St. Luke's Hospital

Nimisha Deb
Ph: 610-954-3582
Email: infolink@slhn.org

Danville

Geisinger Cancer Institute at Geisinger Health

Thomas J Gergel
Ph: 570-271-5251

Greensburg

UPMC Cancer Center - Arnold Palmer Pavilion

John C Flickinger
Ph: 412-647-2811

McKeesport

UPMC Cancer Center at UPMC McKeesport

John C Flickinger
Ph: 412-647-2811

Moon Township

UPMC - Moon

John C Flickinger
Ph: 412-647-2811

Philadelphia

Frankford Hospital Cancer Center - Torresdale Campus

Maria Werner-Wasik
Ph: 215-955-6084

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Maria Werner-Wasik
Ph: 215-955-6084

Pittsburgh

Allegheny Cancer Center at Allegheny General Hospital

Stephen M Karlovits
Ph: 877-284-2000

St. Clair Memorial Hospital Cancer Center

John C Flickinger
Ph: 412-647-2811

UPMC - Shadyside

John C Flickinger
Ph: 412-647-2811

UPMC Cancer Center at UPMC Passavant

John C Flickinger
Ph: 412-647-2811

UPMC Cancer Center at UPMC St. Margaret

John C Flickinger
Ph: 412-647-2811

West Reading

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center

Albert Yuen
Ph: 610-988-9323

Wilkes-Barre

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

Thomas J Gergel
Ph: 570-271-5251

South Carolina
Greenville

Cancer Centers of the Carolinas - Faris Road

David L Grisell
Ph: 864-241-6251

CCOP - Greenville

David L Grisell
Ph: 864-241-6251

Greer

Cancer Centers of the Carolinas - Greer Radiation Oncology

David L Grisell
Ph: 864-241-6251

Seneca

Cancer Centers of the Carolinas - Seneca

David L Grisell
Ph: 864-241-6251

Spartanburg

Cancer Centers of the Carolinas - Spartanburg

David L Grisell
Ph: 864-241-6251

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

Patricia C Griffin
Ph: 800-486-5941

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Sioux Falls

Sanford Cancer Center at Sanford USD Medical Center

Preston D. Steen
Ph: 701-234-6161

Tennessee
Knoxville

Thompson Cancer Survival Center

Daniel D Scaperoth
Ph: 865-541-1812

Texas
Galveston

University of Texas Medical Branch

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

League City

UTMB Cancer Center at Victory Lakes

Martin Colman
Ph: 409-772-1950
Email: clinical.research@utmb.edu

Lubbock

Covenant Medical Center

Paul Joseph Anderson
Ph: 806-725-8000
Email: jaccresearch@covhs.org

Vermont
Burlington

University of Vermont Medical Center

Steven P Emmons
Ph: 802-656-8990

Virginia
Falls Church

Inova Fairfax Hospital

Samir P Kanani
Ph: 703-208-6650

Richmond

Virginia Commonwealth University Massey Cancer Center

Douglas W Arthur
Ph: 804-628-1939

Washington
Kennewick

Tri-Cities Cancer Center

George E. Laramore
Ph: 206-616-8289

Longview

Lower Columbia Regional Cancer Center at PeaceHealth-St. John Medical Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Mount Vernon

Skagit Valley Hospital Cancer Care Center

George E. Laramore
Ph: 206-616-8289

Seattle

University Cancer Center at University of Washington Medical Center

George E. Laramore
Ph: 206-616-8289

Virginia Mason Medical Center

Huong T. Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

Vancouver

Southwest Washington Medical Center Cancer Center

Matthew C Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Yakima

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Sean F. Cleary
Ph: 877-902-3324

Wisconsin
Green Bay

St. Mary's Hospital Medical Center - Green Bay

Gregory M. Cooley
Ph: 920-433-8889

St. Vincent Hospital Regional Cancer Center

Gregory M. Cooley
Ph: 920-433-8889

Marinette

Bay Area Cancer Care Center at Bay Area Medical Center

Gregory M. Cooley
Ph: 920-433-8889

Mukwonago

D.N. Greenwald Center

Wingate F. Clapper
Ph: 262-928-7632

Oconomowoc

Regional Cancer Center at Oconomowoc Memorial Hospital

Wingate F. Clapper
Ph: 262-928-7632

Sturgeon Bay

Door County Cancer Center at Door County Memorial Hospital

Gregory M. Cooley
Ph: 920-433-8889

Waukesha

Waukesha Memorial Hospital Regional Cancer Center

Wingate F. Clapper
Ph: 262-928-7632

Canada

Saskatchewan
Regina

Allan Blair Cancer Centre at Pasqua Hospital

Tak Hing P Tai
Ph: 306-766-2213

Israel

Tel Aviv

Tel-Aviv Sourasky Medical Center

Felix Bokstein
Ph: 011-972-3-6974761
Email: mop@tasmc.health.gov.il

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01730950
ClinicalTrials.gov processed this data on April 09, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.